Search

90 evidence records

• Clinical Trial NCT05592093 Phase 2|Phase 3
  Healthy Ageing|Antioxidative Stress
  Subject: Hong Shen; 红参; Red Ginseng; Radix et Rhizoma Ginseng Rubra;Ginseng Radix et Rhizoma Rubra · view herb →
• Clinical Trial NCT01699074 Phase 1
  Type 2 Diabetes|Metabolic Syndrome
  Subject: Hong Shen; 红参; Red Ginseng; Radix et Rhizoma Ginseng Rubra;Ginseng Radix et Rhizoma Rubra · view herb →
• Clinical Trial NCT00255307 Phase 2
  Upper Respiratory Infection
  Subject: Xi Yang Shen; 西洋参; American Ginseng; Panacis Quinquefolii Radix;Radix Panacis Quinquefolii · view herb →
• Clinical Trial NCT01578837 Phase 1|Phase 2
  Diabetes Mellitus Type 2|Hypertension
  Subject: Xi Yang Shen; 西洋参; American Ginseng; Panacis Quinquefolii Radix;Radix Panacis Quinquefolii · view herb →
• Clinical Trial NCT00527969 Phase 2
  Memory|Learning|Attention|Cognition|Well-Being
  Subject: Xi Yang Shen; 西洋参; American Ginseng; Panacis Quinquefolii Radix;Radix Panacis Quinquefolii · view herb →
• Clinical Trial NCT00965822 Phase 2
  Upper Respiratory Tract Infections
  Subject: Xi Yang Shen; 西洋参; American Ginseng; Panacis Quinquefolii Radix;Radix Panacis Quinquefolii · view herb →
• Clinical Trial NCT02161198 Phase 2
  Healthy
  Subject: Ren Shen; 人参; Ginseng ;Ginseng; Radix et Rhizoma Ginseng;Ginseng Radix et Rhizoma · view herb →
• Clinical Trial NCT01854164
  Hyperglycemia
  Subject: Ren Shen; 人参; Ginseng ;Ginseng; Radix et Rhizoma Ginseng;Ginseng Radix et Rhizoma · view herb →
• Clinical Trial NCT02392819
  Postprandial Blood Glucose Regulation
  Subject: Ren Shen; 人参; Ginseng ;Ginseng; Radix et Rhizoma Ginseng;Ginseng Radix et Rhizoma · view herb →
• Clinical Trial NCT02763280
  Osteopenia
  Subject: Ren Shen; 人参; Ginseng ;Ginseng; Radix et Rhizoma Ginseng;Ginseng Radix et Rhizoma · view herb →
• Clinical Trial NCT06013293
  Post Operative Pain
  Subject: Zinc Oxide; ZINC oxide · view ingredient →
• Clinical Trial NCT05899075
  Haemophilia
  Subject: Xylitol · view ingredient →
• Clinical Trial NCT05671965
  Energy Intake|Gastrointestinal Hormones|Glycemic Control|Appetite|Satiation
  Subject: Xylitol · view ingredient →
• Clinical Trial NCT06108921
  Chronic Rhinosinusitis|Postoperative Care
  Subject: Xylitol · view ingredient →
• Clinical Trial NCT05711212
  Resting Energy Expenditure
  Subject: Xanthohumol; CHEBI:134289; xanthohumol(1-); 2',4,4'-trihydroxy-6'-methoxy-3-prenylchalcone; 3-hydroxy-6-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-5-methoxy-2-(3-methylbut-2-en-1-yl)phenolate · view ingredient →
• Clinical Trial NCT06069804 Phase 4
  Pain, Postoperative
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT05887804 Phase 4
  Keloid|Stem Cell
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT05939817 Phase 4
  Keloid|Stem Cell
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT05844618 Phase 4
  Atopic Dermatitis
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT05806021 Phase 4
  Primary Gonarthrosis
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT06079645 Phase 4
  Lichen Sclerosus of External Female Genital Organs
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT05997238 Phase 4
  Osteoarthritis, Knee
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT06170593
  Acne Vulgaris
  Subject: Volon; Triamcinolone; ZINC03882036; Triamcinolon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; Fluoxyprednisolone; BRN 2341955; STOCK1N-56723; 9alpha-Fluoro-16alpha-hydroxyprednisolone · view ingredient →
• Clinical Trial NCT05939726
  Palmar-Plantar Erythrodysesthesia|Palmar-Plantar Erythrodysesthesia Due to Cytotoxic Therapy
  Subject: Vitamin E; T1539_SIGMA; NSC 82623; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; (+-)-alpha-Tocopherol; BRN 0094012; 5,7,8-Trimethyltocol; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; 6-Chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-; T3634_SIGMA · view ingredient →
• Clinical Trial NCT05787925
  Lichen Planus
  Subject: Vitamin E; T1539_SIGMA; NSC 82623; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; (+-)-alpha-Tocopherol; BRN 0094012; 5,7,8-Trimethyltocol; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; 6-Chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-; T3634_SIGMA · view ingredient →
• Clinical Trial NCT05906498 Phase 3
  Psoriasis Vulgaris
  Subject: Vitamin E; T1539_SIGMA; NSC 82623; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; (+-)-alpha-Tocopherol; BRN 0094012; 5,7,8-Trimethyltocol; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; 6-Chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-; T3634_SIGMA · view ingredient →
• Clinical Trial NCT05984173 Phase 4
  Dry Socket
  Subject: Vitamin E; T1539_SIGMA; NSC 82623; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; (+-)-alpha-Tocopherol; BRN 0094012; 5,7,8-Trimethyltocol; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; 6-Chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-; T3634_SIGMA · view ingredient →
• Clinical Trial NCT05675163
  Oxidative Stress|Inflammation
  Subject: Vitamin K2; (2'Z,6'E,10'E)-Menaquinone 4 · view ingredient →
• Clinical Trial NCT05942053 Phase 4
  Chronic Kidney Diseases
  Subject: Vitamin K2; (2'Z,6'E,10'E)-Menaquinone 4 · view ingredient →
• Clinical Trial NCT05742295 Phase 4
  Antibiotic Side Effect
  Subject: Vitamin K; Monodion; NSC270681; 2-Methyl-3-phythyl-1,4-naphthochinon; [r-[r*,R*-(E)]]-2-Methyl-3-(3-7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, (R-(R*,R*-(E)))-; Phythyl-menadion; HSDB 3162; Phytomenadionum; MolPort-001-785-978 · view ingredient →
• Meta-Analysis CRD42023408843
  Diabetic macular edema is the major cause of vision loss due to diabetic retinopathy.DME pathogenesis includes genetic transmission, increased production of free radicals, advanced glycosylation end products, inflammatory factors, and vascular endothelial growth factors. Interventions: The patients in the experimental group received triamcinolone treatment along with an bevacizumab medication, whereas the patients in the control group received only an bevacizumab medication.
  Subject: Volon; Triamcinolone; triamcinolone; 124-94-7; Fluoxyprednisolone; Aristocort; Triamcinolon; Kenacort; Rodinolone; Delphicort · view ingredient →
• Meta-Analysis CRD42023491783
  Malocclusion is the domain under study and orthodontic treatment is done to correct this malocclusion. Accelerating the orthodontic tooth movement will reduce the overall treatment duration. There are multiple external agents which increases the rate of tooth movement and there are various animal studies which have stated the effect Vitamin D and it's impact in moving the teeth. In this study the potential benefit of Vitamin D in influencing the orthodontic tooth movement will be studied.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023470800
  Endometriosis and primary dysmenorrhea related pain
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023470087
  Autoimmune and Rheumatic Diseases Vitamin D in Autoimmune and Rheumatic Diseases
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023449899
  Employer loose-related hip fractures are generally considered the most severe type of osteoporotic fracture. Studies have shown that more than one in five patients dies within 1 year of a hip fracture. Survivors may need more social and care. The increased social and economic burden associated with osteoporosis-related fractures globally makes their prevention a major public health goal. Practice guidelines recommend vitamin D supplementation in older adults to prevent fractures in patients with
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023432314
  Sufficient levels of vitamin D are essential for the absorption of calcium, maintaining healthy bones, and supporting the immune system. These factors directly affect both the mother and the developing fetus. Previous meta-analyses have indicated that supplementing with vitamin D during pregnancy might decrease the likelihood of complications like preeclampsia and gestational diabetes. However, there is no consensus on the appropriate timing and dosage of vitamin D supplementation. Furthermore,
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023468978
  The systematic review investigates the role of vitamin D supplementation in the management and treatment of inflammatory bowel disease (IBD). Inflammatory bowel disease encompasses chronic inflammatory conditions of the gastrointestinal tract, primarily including Crohn's disease and ulcerative colitis. IBD is characterized by symptoms such as abdominal pain, diarrhea, fatigue, and weight loss, and it can significantly impact the quality of life of affected individuals. The review aims to synthes
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023468744
  Vitamins, essential organic compounds, play a crucial role in maintaining health and physiological balance. Their importance extends to orthodontics, influencing oral health, bone metabolism, and treatment outcomes. The intricate relationship between orthodontics and vitamins, though apparent in various facets of oral health, remains an area of research with vast potential. Given the myriad ways vitamins impact bone health, gum vitality, tooth enamel strength, and overall healing, understanding
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023466307
  A systematic review is studying the effects of vitamin D supplementation in patients with polycystic ovary syndrome. This disease is a very common endocrine condition in women of childbearing age, causing a series of consequences such as reproductive, metabolic and psychological problems, including: infertility, complications during pregnancy, conditions for other comorbidities such as type 2 diabetes, anxiety, depression and consequently a low quality of life.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023462014
  Traumatic insult to the brain leads to primary or secondary injuries. Primary injuries result from the primary insult to the brain parenchyma While secondary injuries result from immune response and free radical damage to the neural cells following the primary insult. Vitamin D is a fat soluble vitamin with multiple biological effects, its antioxidant and anti-immune effects have been hypothesized to attenuate the process of secondary brain injury and this has been proven in animal studies.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023433300
  Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. It is estimated that the incidence of neuropathic pain ranges from 2 – 40% of the adult population. Pain that arises continuously will have a negative impact on sufferers, causing depression, sleep disturbances, mood disorders, physical and social functioning disorders. Neuropathic pain is associated with poor emotional and physical functioning. The current management of neuropathic pain is sti
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023430406
  This systematic review is focusing on effect of vitamin D supplementation on the serum level of anti-müllerian hormone.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023430097
  Metabolic Syndrome
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023429510
  Inflammation seems to be common in CKD. Dialysis patients especially seem to be higher in inflammation biomarkers because their kidneys did not clean the body of waste products, did not eliminate inflammatory biomarkers from the body which led to the increase of Inflammatory cytokines like CRP, Il-6...etc.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023416114
  Meta-analyses were included for data extraction if the exposure was calcium and vitamin D supplementation irrespective of the ethnic factors, gender, country or area of participants.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023408324
  Thrombocytopenias
  Subject: Trans-caffeic acid; Caffeic Acid; caffeic acid; 3,4-Dihydroxycinnamic acid; 331-39-5; 501-16-6; 3-(3,4-dihydroxyphenyl)acrylic acid; 3,4-Dihydroxybenzeneacrylic acid; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid · view ingredient →
• Meta-Analysis CRD42023414975
  Osteoporosis in Duchenne Muscular Dystrophy.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023439691
  Gender Affirmation
  Subject: Trichosanic acid; Punicic Acid; Punicic acid; 544-72-9; Trichosanoic acid; (9Z,11E,13Z)-octadeca-9,11,13-trienoic acid; 9-cis,11-trans,13-cis-octadecatrienoic acid; cis-9,trans-11,cis-13-Octadecatrienoic acid; UNII-VFQ03H211O; VFQ03H211O · view ingredient →
• Meta-Analysis CRD42023432500
  Retinopathy of prematurity is a potentially blinding condition affecting neonates. routine screening is recommended for early detection and treatment to prevent blindness. The procedure is painful and topical anaesthesia that is currently recommended for pain relief does not completely alleviate pain.
  Subject: Saccharose; Sucrose; sucrose; 57-50-1; sugar; Table sugar; Cane sugar; White sugar; D-Sucrose; Rohrzucker · view ingredient →
• Meta-Analysis CRD42023412200
  Preterm infants with procedural pain in the neonatal intensive care unit.
  Subject: Saccharose; Sucrose; sucrose; 57-50-1; sugar; Table sugar; Cane sugar; White sugar; D-Sucrose; Rohrzucker · view ingredient →
• Meta-Analysis CRD42023492979
  Chronic kidney disease (CKD) is related to bone metabolism disorders including vitamin D deficiency, hypocalcaemia, hyperphosphatemia, and hyperparathyroidism. Vitamin D deficiency is common in chronic kidney disease. Vitamin D is not only important in bone metabolism, but also plays important roles as anti-inflammation, anti-fibrosis, immunomodulator, and anti-tumor. Some guidelines recommended routine measurement of serum 25(OH)D levels and maintaining vitamin D sufficiency. This study aims to
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023451040
  End Stage Renal Disease
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023416960
  The review will be focused on occupational exposure to formaldehyde in adult workers of all gender, in order to identify biomarkers of exposure or biomarkers of effect. Only studies involving adult workers of all gender who are occupationally exposed to formaldehyde will be considered eligible.
  Subject: Formaldehyde; formalin; methanal; Paraformaldehyde; 50-00-0; formol; Oxomethane; Paraform; Methylene oxide; Formic aldehyde · view ingredient →
• Meta-Analysis CRD42023483712
  In this review, the effect of vitamin D supplements on the number of relapses of multiple sclerosis will be studied.
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023474020
  Vaginal atrophy, vulvovaginal atrophy, vaginal dryness, dyspareunia, and sexual inactivity and dysfunction as major symptoms of menopause and postmenopause
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023448717
  Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The increase in glucose concentration that occurs in Type 2 Diabetes Mellitus (DM2) usually leads to damage to target organs (eyes, kidneys, nervous and cardiovascular systems). Currently, the disease affects 537 million adults, aged between 20 and 79 years. Regarding the pathophysiology of the disease, there is evidence that oxidative stress pla
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · view ingredient →
• Meta-Analysis CRD42023422165
  Nowadays, tooth loss is a problem that is felt in our population. The area of endodontics aims to maintaining the dental elements that are compromised in the pulp and periapical tissues, preventing the proliferation of microorganisms and, consequently, the loss of the tooth. The materials used in endodontic treatment are constantly evolving, especially due to the introduction of new sealers in the market. Different brands claim to be biocompatible materials enhancing the natural regeneration of
  Subject: Calcium silicate; Calcium Silicate; Silicic acid, calcium salt; 1344-95-2; Dicalcium silicate; Calsil; Micro-cel; Calcium hydrosilicate; CS lafarge; Toyofine A · view ingredient →
• Meta-Analysis CRD42023420817
  Liver function indices including Aspartate aminotransferase (AST), Alanine transaminase (ALT), Alkaline Phosphatase(ALP), and gamma-glutamyl transferase (GGT).
  Subject: Silymarin; Silybin; 65666-07-1; Legalon; 84604-20-6; (2R,3R)-3,5,7-trihydroxy-2-[(2R)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one; Silibin; 142796-20-1; 36804-17-8; Apihepar · view ingredient →
• Meta-Analysis CRD42023482601
  In people living with COPD we will study: 1) Glucocorticoid-induced diabetes defined as a new-onset diabetes following exposure to glucocorticoids in people without pre-existing diabetes; and 2) Glucocorticoid-induced hyperglycaemia defined as worsening hyperglycaemia in people with diabetes following exposure to glucocorticoids.
  Subject: 4-pregnene-17α,20β,21-triol-3,11-dione; Hydrocortisone; hydrocortisone; Cortisol; 50-23-7; Acticort; Cetacort; Cortef; Hydrasson; Hydrocortisyl · view ingredient →
• Meta-Analysis CRD42023446535
  Probable transitional circulatory shock (as defined by the author)
  Subject: Vasopressin; Pressyn; 8-L-Lysine vasopressin; 3-(Phenylalanine)-8-lysine oxytocin; BDBM627975; CVD-0019448; Q60496436; 6-amino-2-{[(2S)-1-{[(4R,7S,10S,13S,16S,19R)-19-amino-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)hexanamide · view ingredient →
• Published Reference 35784691
  nephrotic syndrome; renal fibrosis; fibrosis of the glomeruli and interstitium; glomerulosclerosis; fibrosis of sclerotic glomeruli; Focal segmental glomerulosclerosis; fibrosis
  Subject: Yi Shen Hua Shi Ke Li; 益肾化湿颗粒; Yi Shen Hua Shi Granule; Yishen Huashi Granule · view formula →
  Yi-Shen-Hua-Shi Granule Alleviates Adriamycin-Induced Glomerular Fibrosis by Suppressing the BMP2/Smad Signaling Pathway
• Published Reference 36116201
  acute lung injury; allergic rhinitis; upper respiratory infections; nasal inflammation; acute respiratory distress syndrome; allergic inflammatory reaction of the nasal mucosa; olfactory abnormality; olfactory dysfunction
  Subject: Shu Feng Jie Du Jiao Nang; 疏风解毒胶囊; Shufeng Jiedu Capsule · view formula →
  Shufeng Jiedu capsule ameliorates olfactory dysfunction via the AMPK/mTOR autophagy pathway in a mouse model of allergic rhinitis
• Published Reference 36002086
  laryngitis; lung inflammation; tonsillitis; pharyngitis; infectious diseases; colds; upper respiratory tract infections; acute lung injury; tumor; lung damage
  Subject: Shu Feng Jie Du Jiao Nang; 疏风解毒胶囊; Shufeng Jiedu Capsule · view formula →
  Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF-κB to alleviate LPS-induced ALI
• Published Reference 24647112
  acute lung injury; lipopolysaccharide-induced acute lung injury
  Subject: Shu Feng Jie Du Jiao Nang; 疏风解毒胶囊; Shufeng Jiedu Capsule · view formula →
  Shufeng Jiedu Capsule protect against acute lung injury by suppressing the MAPK/NF-κB pathway
• Published Reference 31649545
  Hepatocellular carcinoma
  Subject: Zuojin Wan; 左金丸; Zuojin Pill; Zuo Pill · view formula →
  Integrating Network Pharmacology and Pharmacological Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing Hepatocellular Carcinoma
• Published Reference 34942456
  gastrointestinal diseases; tumor; colorectal cancer; cancer
  Subject: Zuojin Jiaonang; 左金胶囊; Zuojin Capsule; Zuo Jin Capsule · view formula →
  Integrating network pharmacology deciphers the action mechanism of Zuojin capsule in suppressing colorectal cancer
• Published Reference 36386214
  diabetes; diabetic nephropathy
  Subject: Zuo Gui Wan; 左归丸; Zuo Gui Pill · view formula →
  Zuogui Wan ameliorates high glucose-induced podocyte apoptosis and improves diabetic nephropathy in db/db mice
• Published Reference 35592785
  spinal osteoporosis; spinal glucocorticoid-induced osteoporosis
  Subject: Zuo Gui Wan; 左归丸; Zuo Gui Pill · view formula →
  Zuo-Gui-Wan Aqueous Extract Ameliorates Glucocorticoid-Induced Spinal Osteoporosis of Rats by Regulating let-7f and Autophagy
• Published Reference 35483559
  senile disorders; age-related disorders; osteoporosis
  Subject: Zuo Gui Wan; 左归丸; Zuo Gui Pill · view formula →
  Zuogui Wan slowed senescence of bone marrow mesenchymal stem cells by suppressing Wnt/β-catenin signaling
• Published Reference 15334678
  (condition not recorded)
  Subject: Zuo Gui Wan; 左归丸; Zuo Gui Pill · view formula →
  Effects of Zuogui Wan on neurocyte apoptosis and down-regulation of TGF-beta1 expression in nuclei of arcuate hypothalamus of monosodium glutamate -liver regeneration rats
• Published Reference 35873590
  (condition not recorded)
  Subject: ZHI ZI HOU PO TANG; 栀子厚朴汤; Zhi Zi Hou Po Decoction · view formula →
  Potential Anti-Depressive Effects and Mechanisms of Zhi-Zi Hou-Po Decoction Using Behavioral Despair Tests Combined With in Vitro Approaches
• Published Reference 34690756
  (condition not recorded)
  Subject: ZHI ZI HOU PO TANG; 栀子厚朴汤; Zhi Zi Hou Po Decoction · view formula →
  Integrated Network Pharmacology Analysis and Experimental Validation to Investigate the Mechanism of Zhi-Zi-Hou-Po Decoction in Depression
• Published Reference 33569009
  (condition not recorded)
  Subject: ZHI ZI CHI TANG; 栀子豉汤; Zhi Zi Chi Decoction; Zhizi Chi Decoction · view formula →
  Predicting a Potential Link to Antidepressant Effect: Neuroprotection of Zhi-zi-chi Decoction on Glutamate-induced Cytotoxicity in PC12 Cells
• Published Reference 32982748
  neurodegenerative disorders; headaches
  Subject: Zhengtian Jiaonang; 正天胶囊; Zhengtian Capsule; Zheng Tian Capsule · view formula →
  The Anti-Depression-Like Effects of Zhengtian Capsule via Induction of Neurogenesis and the Neurotrophic Signaling Pathway
• Published Reference 36257219
  kidney diseases; chronic kidney disease; renal interstitial fibrosis; Exogenous Febrile Disease; renal function impairment; unilateral ureteral obstruction
  Subject: Zhen Wu Tang; 真武汤; Zhenwu Decoction; Zhen Wu Decoction · view formula →
  Zhen Wu decoction represses renal fibrosis by invigorating tubular NRF2 and TFAM to fuel mitochondrial bioenergetics
• Published Reference 36099983
  TCM syndrome; chronic heart failure; Cardiac hypertrophy; Yang deficiency; cardiac fibrosis; cardiac hypertrophy; dampness retention syndrome
  Subject: Zhen Wu Tang; 真武汤; Zhenwu Decoction; Zhen Wu Decoction · view formula →
  Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase) - cGMP (cyclic guanosine monophosphate) - PKG (protein kinase G) pathway
• Published Reference 32765277
  proteinuria; Immunoglobulin; IgAN; renal dysfunction; kidney diseases; renal diseases; glomerulonephritis; nephropathy
  Subject: Zhen Wu Tang; 真武汤; Zhenwu Decoction; Zhen Wu Decoction · view formula →
  Zhen-Wu-Tang Protects IgA Nephropathy in Rats by Regulating Exosomes to Inhibit NF-κB/NLRP3 Pathway
• Published Reference 30991182
  kidney diseases; Inflammation mediated podocyte injury; membranous nephropathy
  Subject: Zhen Wu Tang; 真武汤; Zhenwu Decoction; Zhen Wu Decoction · view formula →
  Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-κB pathway and NLRP3 inflammasome
• Published Reference 35151834
  hyperlipidemia
  Subject: ZE XIE TANG; 泽泻汤; Ze Xie Decoction; Zexie Decoction · view formula →
  Zexie Tang targeting FKBP38/mTOR/SREBPs pathway improves hyperlipidemia
• Published Reference 34566646
  non-alcoholic fatty liver disease
  Subject: ZE XIE TANG; 泽泻汤; Ze Xie Decoction; Zexie Decoction · view formula →
  Integrating Network Pharmacology and RT-qPCR Analysis to Investigate the Mechanisms Underlying ZeXie Decoction-Mediated Treatment of Non-alcoholic Fatty Liver Disease
• Published Reference 26825573
  (condition not recorded)
  Subject: Yueju Wan; 越鞠丸; Yueju Pill; Yue Ju Pill · view formula →
  Instant and Lasting Down-Regulation of NR1 Expression in the Hippocampus is Associated Temporally with Antidepressant Activity After Acute Yueju
• Published Reference 33268963
  inflammatory injury; inflammation; acute pancreatitis; acute lung injury; acute kidney injury; acid-base balance disorders; lung and kidney edema
  Subject: Yue Bi Tang; 越婢汤; Yue Bi Decoction; Yuebi Decoction · view formula →
  Effects of Yue-Bi-Tang on water metabolism in severe acute pancreatitis rats with acute lung-kidney injury
• Published Reference 34875251
  Can-induced inflammation
  Subject: Yu Ping Feng San; 玉屏风散; Yu Ping Feng Powder · view formula →
  Study on the mechanism of Yupingfeng powder in the treatment of immunosuppression based on UPLC⁃QTOF⁃MS, network pharmacology and molecular biology verification
• Published Reference 34135758
  immune disorders; cancers; lung cancer; solid tumors
  Subject: Yu Ping Feng San; 玉屏风散; Yu Ping Feng Powder · view formula →
  The Mechanisms of Yu Ping Feng San in Tracking the Cisplatin-Resistance by Regulating ATP-Binding Cassette Transporter and Glutathione S-Transferase in Lung Cancer Cells
• Published Reference 32076408
  DSG1 deficiency; airway hyperresponsiveness; chronic asthma; asthma
  Subject: Yu Ping Feng San; 玉屏风散; Yu Ping Feng Powder · view formula →
  A Chinese Prescription Yu-Ping-Feng-San Administered in Remission Restores Bronchial Epithelial Barrier to Inhibit House Dust Mite-Induced Asthma Recurrence
• Published Reference 30668371
  Atopic dermatitis; TJ defects; allergic inflammation; allergic inflammatory skin disease
  Subject: Yu Ping Feng San; 玉屏风散; Yu Ping Feng Powder · view formula →
  Yu-Ping-Feng-San ameliorates recurrent allergic inflammation of atopic dermatitis by repairing tight junction defects of the epithelial barrier
• Published Reference 30131696
  Chemo-resistance; lung cancer; cancer; non-small cell lung cancer
  Subject: Yu Ping Feng San; 玉屏风散; Yu Ping Feng Powder · view formula →
  The WT1/MVP-Mediated Stabilization on mTOR/AKT Axis Enhances the Effects of Cisplatin in Non-small Cell Lung Cancer by a Reformulated Yu Ping Feng San Herbal Preparation
• Published Reference 29311942
  Asthma; asthma
  Subject: Yu Ping Feng San; 玉屏风散; Yu Ping Feng Powder · view formula →
  Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice
• Published Reference 25586308
  (condition not recorded)
  Subject: Yu Ping Feng San; 玉屏风散; Yu Ping Feng Powder · view formula →
  Yu Ping Feng San, an Ancient Chinese Herbal Decoction, Induces Gene Expression of Anti-viral Proteins and Inhibits Neuraminidase Activity
• Published Reference 31357410
  metabolic disease; Kidney-yang deficiency syndrome; neuro-endocrine disorder
  Subject: You Gui Wan; 右归丸; You Gui Pill; Yougui Pill · view formula →
  Integrated Systems Pharmacology, Urinary Metabonomics, and Quantitative Real-Time PCR Analysis to Uncover Targets and Metabolic Pathways of the You-Gui Pill in Treating Kidney-Yang Deficiency Syndrome